These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 33510107)
1. Markers of ineffective erythropoiesis in non-transfusion dependent β-thalassaemia. Khairullah S; Jackson N Med J Malaysia; 2021 Jan; 76(1):41-45. PubMed ID: 33510107 [TBL] [Abstract][Full Text] [Related]
2. Imbalance of erythropoiesis and iron metabolism in patients with thalassemia. Huang Y; Lei Y; Liu R; Liu J; Yang G; Xiang Z; Liang Y; Lai Y Int J Med Sci; 2019; 16(2):302-310. PubMed ID: 30745811 [No Abstract] [Full Text] [Related]
3. Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions. Porter JB; Cappellini MD; Kattamis A; Viprakasit V; Musallam KM; Zhu Z; Taher AT Br J Haematol; 2017 Jan; 176(2):288-299. PubMed ID: 27917462 [TBL] [Abstract][Full Text] [Related]
4. Erythropoiesis and Iron Homeostasis in Non-Transfusion-Dependent Thalassemia Patients with Extramedullary Hematopoiesis. Huang Y; Liu R; Wei X; Liu J; Pan L; Yang G; Lai Y Biomed Res Int; 2019; 2019():4504302. PubMed ID: 30834265 [TBL] [Abstract][Full Text] [Related]
5. Erythropoiesis-driven regulation of hepcidin in human red cell disorders is better reflected through concentrations of soluble transferrin receptor rather than growth differentiation factor 15. Fertrin KY; Lanaro C; Franco-Penteado CF; de Albuquerque DM; de Mello MR; Pallis FR; Bezerra MA; Hatzlhofer BL; Olbina G; Saad ST; da Silva Araújo A; Westerman M; Costa FF Am J Hematol; 2014 Apr; 89(4):385-90. PubMed ID: 24860871 [TBL] [Abstract][Full Text] [Related]
6. The effect of erythroferrone suppression by transfusion on the erythropoietin-erythroferrone-hepcidin axis in transfusion-dependent thalassaemia: A pre-post cohort study. Zaman BA; Rasool SO; Abdo JM Br J Haematol; 2023 May; 201(3):547-551. PubMed ID: 36535905 [TBL] [Abstract][Full Text] [Related]
7. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680 [TBL] [Abstract][Full Text] [Related]
8. Prevalence and Risk Factors for Cardiac and Liver Iron Overload in Adults with Thalassemia in Malaysia. Ngim CF; Lee MY; Othman N; Lim SM; Ng CS; Ramadas A Hemoglobin; 2019 Mar; 43(2):95-100. PubMed ID: 31179787 [TBL] [Abstract][Full Text] [Related]
9. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study. Pasricha SR; Frazer DM; Bowden DK; Anderson GJ Blood; 2013 Jul; 122(1):124-33. PubMed ID: 23656728 [TBL] [Abstract][Full Text] [Related]
10. Iron overload in thalassemia: different organs at different rates. Taher AT; Saliba AN Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):265-271. PubMed ID: 29222265 [TBL] [Abstract][Full Text] [Related]
11. Identification and key management of non-transfusion-dependent thalassaemia patients: not a rare but potentially under-recognised condition. Viprakasit V; Tyan P; Rodmai S; Taher AT Orphanet J Rare Dis; 2014 Sep; 9():131. PubMed ID: 25265971 [TBL] [Abstract][Full Text] [Related]
12. Morbidities in non-transfusion-dependent thalassemia. Saliba AN; Taher AT Ann N Y Acad Sci; 2016 Mar; 1368(1):82-94. PubMed ID: 27186941 [TBL] [Abstract][Full Text] [Related]
13. Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions. Cui R; Gale RP; Zhu G; Xu Z; Qin T; Zhang Y; Huang G; Li B; Fang L; Zhang H; Pan L; Hu N; Qu S; Xiao Z Leuk Res; 2014 May; 38(5):545-50. PubMed ID: 24598841 [TBL] [Abstract][Full Text] [Related]
14. Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia. Bou-Fakhredin R; Bazarbachi AH; Chaya B; Sleiman J; Cappellini MD; Taher AT Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29261151 [TBL] [Abstract][Full Text] [Related]
15. Mechanisms of plasma non-transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients. Porter JB; Walter PB; Neumayr LD; Evans P; Bansal S; Garbowski M; Weyhmiller MG; Harmatz PR; Wood JC; Miller JL; Byrnes C; Weiss G; Seifert M; Grosse R; Grabowski D; Schmidt A; Fischer R; Nielsen P; Niemeyer C; Vichinsky E Br J Haematol; 2014 Dec; 167(5):692-6. PubMed ID: 25209728 [TBL] [Abstract][Full Text] [Related]
16. Soluble hemojuvelin in transfused and untransfused thalassaemic subjects. Ferro E; Di Pietro A; Visalli G; Piraino B; Salpietro C; La Rosa MA Eur J Haematol; 2017 Jan; 98(1):67-74. PubMed ID: 27440164 [TBL] [Abstract][Full Text] [Related]
17. Non-Transfusion-Dependent Thalassemia: A Panoramic Review. Shash H Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295656 [TBL] [Abstract][Full Text] [Related]
18. Accuracy of serum transferrin receptor levels in the diagnosis of iron deficiency among hospital patients in a population with a high prevalence of thalassaemia trait. Ong KH; Tan HL; Tam LP; Hawkins RC; Kuperan P Int J Lab Hematol; 2008 Dec; 30(6):487-93. PubMed ID: 18983300 [TBL] [Abstract][Full Text] [Related]
19. Ineffective erythropoiesis and regulation of iron status in iron loading anaemias. Camaschella C; Nai A Br J Haematol; 2016 Feb; 172(4):512-23. PubMed ID: 26491866 [TBL] [Abstract][Full Text] [Related]
20. Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of β-thalassemia with blood transfusions. Kalleda N; Flace A; Altermatt P; Ingoglia G; Doucerain C; Nyffenegger N; Dürrenberger F; Manolova V Haematologica; 2023 Oct; 108(10):2703-2714. PubMed ID: 37165842 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]